The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
The company said it plans to use the proceeds raised in the private placement primarily to fund its Hodgkin's lymphoma test clinical trial.
In Science this week: two proteins may help treat muscular dystrophy, and more.
The firm's first assay will be for Hodgkin lymphoma, but a liquid biopsy test for prostate cancer has also shown strong predictive power in initial validation data.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
Using a mass spec-based proteogenomic approach, the researchers identified commonalities in neoantigen presentation across mantle cell lymphoma patients.
MLL will be the first European user of Illumina's new high-throughput sequencing platform, the NovaSeq.
In PNAS this week: common, not rare ERAP1 variants linked to ankylosing spondylitis, recurrent VAV1 mutations in peripheral T-cell lymphoma, and more.
Roche has licensed and plans to commercialize the circulating tumor DNA technology, which the Stanford researchers dubbed CAPP-seq.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.